Empower Therapeutics Inc. Granted Exclusive License to Develop Digital Therapeutics Platform for Neuromodulation of Pain Sensitivity

Technology developed by scientists at the University of Maryland, Baltimore (UMB) and the University of Birmingham, U.K.

BALTIMORE, Aug. 19, 2021 /PRNewswire/ — Empower Therapeutics Inc., a Baltimore-based startup, has secured worldwide, exclusive rights to a simple, reliable brainwave biomarker for pain sensitivity. Empower plans to leverage the technology, which is jointly owned by the University of Maryland, Baltimore (UMB) and the University of Birmingham, U.K., to develop a cutting-edge digital therapeutics platform to determine and modify pain sensitivity for chronic pain therapy.   

The technology, which analyzes brain waves using EEG to determine an individual’s sensitivity to pain, was developed by Andrew Furman, an Empower Therapeutics co-founder and UMB graduate student, along with his team of advisors, including Dave Seminowicz, Ph.D., of UMB and Ali Mazaheri, Ph.D., of the University of Birmingham. Identifying a biomarker for pain sensitivity enables targeting of therapies to reverse the underlying changes in the central nervous system.

Steven Rothenberg, M.D., CEO and co-founder of Empower Therapeutics, said, “Chronic pain is difficult to treat and its development often does not correlate with an anatomic cause or injury load. By building a digital therapeutics platform for neuromodulation of pain sensitivity, we can leverage this biomarker to objectively repair the mind-body connection for a variety of pain conditions.”

Click here to read the entire press release.